Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 3
Journal homepage
1,253
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

Per Edlund Department of Oncology, Gävle Hospital, Sweden
,
Johan Ahlgren Department of Oncology, Gävle Hospital, Sweden
,
Karsten Bjerre the DBCG Registry, Copenhagen, Denmark
,
Michael Andersson Department of Oncology, Rigshospitalet, Copenhagen, Denmark
,
Jonas Bergh Radiumhemmet, Karolinska Hospital, Stockholm Sweden
,
Henning Mouridsen Department of Oncology, Rigshospitalet, Copenhagen, Denmark
,
Stig B. Holmberg Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
,
Nils-Olof Bengtsson Department of Oncology, Umeå University Hospital, Sweden
,
Erik Jakobsen Department of Oncology, Vejle Hospital, Denmark
,
Susanne Møller the DBCG Registry, Copenhagen, Denmark
,
Henrik Lindman Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
&
Carl Blomqvist Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Department of Oncology, Helsinki University Hospital, Helsinki, FinlandCorrespondence[email protected]
 show all
Pages 329-337 | Received 15 Dec 2010, Accepted 05 Jan 2011, Published online: 08 Feb 2011

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Paula Poikonen-Saksela, Henrik Lindman, Asgerdur Sverrisdottir, Per Edlund, Kenneth Villman, Lena Tennvall Nittby, Søren Cold, Troels Bechmann, Lars Stenbygaard, Bent Ejlertsen, Michael Andersson, Carl Blomqvist, Jonas Bergh & Johan Ahlgren. (2020) Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1. Acta Oncologica 59:7, pages 825-832.
Read now

Articles from other publishers (8)

Anil A. Joy, Larissa J. Vos, Edith Pituskin, Sarah F. Cook, Robert R. Bies, Ann Vlahadamis, Karen King, Sanraj K. Basi, Judith Meza-Junco, John R. Mackey, Avalyn Stanislaus, Vijaya L. Damaraju, Sambasivarao Damaraju & Michael B. Sawyer. (2021) Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer. Clinical Breast Cancer 21:5, pages e584-e593.
Crossref
H. Lindman, M. Andersson, J. Ahlgren, E. Balslev, A. Sverrisdottir, S.B. Holmberg, N.O. Bengtsson, E.H. Jacobsen, A.B. Jensen, J. Hansen, M.K. Tuxen, L. Malmberg, K. Villman, H. Anderson, B. Ejlertsen, J. Bergh & C. Blomqvist. (2018) A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). European Journal of Cancer 94, pages 79-86.
Crossref
Yassine Lalami & Jean Klastersky. (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Critical Reviews in Oncology/Hematology 120, pages 163-179.
Crossref
Michael B. Sawyer, Edith Pituskin, Sambasivarao Damaraju, Robert R. Bies, Larissa J. Vos, Carla. M.M. Prado, Michelle Kuzma, Andrew G. Scarfe, Mark Clemons, Katia Tonkin, Heather-Jane Au, Sheryl Koski, Anil A. Joy, Michael Smylie, Karen King, Diana Carandang, Vijaya L. Damaraju, John Hanson, Carol E. Cass & John R. Mackey. (2016) A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer 16:2, pages 139-144.e3.
Crossref
Jan C. Drooger, Johanna M. van Pelt-Sprangers, Corry Leunis, Agnes Jager & Felix E. de Jongh. (2015) Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study. Medical Oncology 32:4.
Crossref
Francesco Russo, Michele Linsalata, Caterina Clemente, Benedetta D’Attoma, Antonella Orlando, Giovanna Campanella, Francesco Giotta & Giuseppe Riezzo. (2013) The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer 13:1.
Crossref
Gregory R. Pond, William R. Berry, Matthew D. Galsky, Brian A. Wood, Lance Leopold & Guru Sonpavde. (2012) Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 10:4, pages 239-245.
Crossref
Yunwei Han, Zhihao Yu, Shaoyan Wen, Bin Zhang, Xuchen Cao & Xin Wang. (2011) Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Research and Treatment 131:2, pages 483-490.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.